top of page
Search

Cardiac Biomarkers Market Growth, Share & Industry Forecast 2032

  • Writer: Pallavi Garudkar
    Pallavi Garudkar
  • 1 day ago
  • 2 min read
Cardiac Biomarkers Market
Cardiac Biomarkers Market

The global cardiac biomarkers market size was valued at USD 18.62 billion in 2024. The market is projected to grow from USD 20.90 billion in 2025 to USD 47.43 billion by 2032, exhibiting a CAGR of 12.4% during the forecast period. Cardiac biomarkers are proteins, enzymes, or hormones released into the bloodstream when the heart muscle is damaged or under stress. They are essential for diagnosing and monitoring cardiovascular conditions such as acute coronary syndrome (ACS), myocardial infarction, and heart failure. These biomarkers help clinicians quickly assess the severity of cardiac events and improve patient outcomes through timely intervention.



Key Market Drivers:

  1. Increasing Cardiovascular Disease BurdenLifestyle changes, aging demographics, and risk factors like diabetes, hypertension, and obesity are fueling the rise of cardiovascular diseases globally.

  2. Growing Adoption of Point-of-Care TestingPortable and rapid point-of-care (POC) cardiac tests are transforming emergency care by providing swift, accurate results without needing central laboratory infrastructure.

  3. Technological AdvancementsHigh-sensitivity assays (especially for troponin and BNP) offer early detection and better accuracy, supporting improved clinical decision-making.


Market Restraints:

  • Limited Availability of POC Tests in Developing MarketsWhile demand is high, access to advanced rapid tests in low-resource settings remains limited.

  • Testing LimitationsCertain biomarkers, like CK-MB, require time to elevate after cardiac damage, limiting immediate diagnosis.

  • Regulatory Challenges & CostsTesting kits must comply with stringent regulatory standards. High costs for advanced assays limit adoption, especially in emerging economies.


Segmentation Analysis:

By Indication:

  • Acute Coronary Syndrome (expected to grow fastest)

  • Myocardial Infarction

  • Congestive Heart Failure

  • Others

By Biomarker:

  • Troponin (dominates the market)

  • Creatine Kinase-MB (CK-MB)

  • B-type Natriuretic Peptide (BNP)

  • Myoglobin

  • Others


Regional Insights:

  • North America held around 39% market share in 2024, driven by a high burden of heart disease, strong healthcare infrastructure, and adoption of advanced diagnostics.

  • Europe is experiencing steady growth, aided by increased incidence of ACS and heart failure.

  • Asia Pacific is poised for rapid expansion due to growing awareness, rising CVD incidence, and improved medical facilities in countries like China and India.

  • Latin America and Middle East & Africa exhibit potential but face challenges such as costs, access, and infrastructure constraints.


Competitive Landscape:

Key Players:

  • Abbott Laboratories

  • F. Hoffmann-La Roche AG

  • Siemens Healthineers

  • Beckman Coulter (Danaher)

  • Thermo Fisher Scientific

  • Bio-Rad Laboratories

  • bioMérieux


Get Your Customization Research Report:


About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights Pvt. Ltd.

9th Floor, Icon Tower,

Baner - Mahalunge Road, Baner,

Pune-411045, Maharashtra, India.

Phone:

US: +18339092966

UK: +448085020280

APAC: +91 744 740 1245Email: sales@fortunebusinessinsights.com



 
 
 

Comments

bottom of page